First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

BACKGROUND: Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can affect clinical outcomes in patients with multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Gareth J, Davies, Faith E, Gregory, Walter M, Cocks, Kim, Bell, Sue E, Szubert, Alex J, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Child, J Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2010
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/
https://www.ncbi.nlm.nih.gov/pubmed/21131037
http://dx.doi.org/10.1016/S0140-6736(10)62051-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/
https://www.ncbi.nlm.nih.gov/pubmed/21131037
http://dx.doi.org/10.1016/S0140-6736(10)62051-X

Ejemplares similares